PERRIGO Co plc (PRGO): M&A transaction — Perrigo completes sale of Dermacosmetics business for €305.6M upfront, plus contingent €27M

PERRIGO Co plc

Upfront cash €305.6M (incl. €5.6M working capital); up to €27M contingent on net sales milestones over three years.
Brands sold: ACO, Biodermal, Emolium, Iwostin; business generated ~€120M net sales (~5% of adj. op income) in 2025.
Net proceeds will be used primarily for debt reduction, enhancing financial flexibility and strengthening balance sheet.
Divestiture is part of Perrigo's Three-S plan to Stabilize, Streamline, and Strengthen the Company.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 1.0

PERRIGO Co plc completed a disposition involving Karo Healthcare AB for €305.6 million in upfront cash plus up to €27.0 million contingent consideration (closed 2026-04-30).

Action: disposition
Counterparty: Karo Healthcare AB
Consideration: €305.6 million in upfront cash plus up to €27.0 million contingent consideration
Closing: 2026-04-30

Exact text from the filing

On April 30, 2026, the Transaction closed pursuant to the terms of the Agreement. In connection with the closing of the Transaction, Karo made a cash payment to the Company of €305.6 million, including €5.6 million in net working capital adjustments. In addition, the Company may be entitled to additional contingent cash consideration of up to €27.0 million upon

View on SEC.gov

32 m&a transactions filed in the last 30 days. Browse all m&a transactions →

PERRIGO Co plc filing history →

Source: SEC EDGAR

accession 0001585364-26-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.